News Releases

Fractyl Health to Report Third Quarter 2026 Financial Results and Provide Business Updates on November 12, 2026

Nov 06, 2026

Fractyl Health Strengthens Revita Patent Portfolio as It Advances Toward FDA Submission and Potential Commercialization

Oct 30, 2026

Fractyl Health Announces Market Research Highlighting Substantial Patient Interest in a One-Time Procedural Approach to Post-GLP-1 Weight Maintenance

Oct 29, 2026

Fractyl Health Sharpens Focus on Revita Following Positive Pivotal Results, Advancing Toward Planned FDA De Novo Submission in Post-GLP-1 Weight Maintenance

Oct 22, 2026

Fractyl Health's Revita Meets Six-Month Co-Primary Endpoint in Ongoing REMAIN-1 Pivotal Study, With Highly Statistically Significant Reduction in Weight Regain After GLP-1 Discontinuation

Oct 16, 2026

Fractyl Health to Participate in Upcoming September Investor Conferences

Sep 09, 2026

Fractyl Health to Host Virtual Commercial Strategy Day on Tuesday, September 1, 2026: The Potential Path to Commercializing Revita®, a Procedural Therapy for Post-GLP-1 Weight Maintenance

Aug 20, 2026

Fractyl Health Reports Second Quarter 2026 Financial Results and Business Updates

Aug 10, 2026

Fractyl Health to Report Second Quarter 2026 Financial Results and Provide Business Updates on August 10, 2026

Aug 03, 2026

Investor Relations Contacts

Brian Luque, Head of Investor Relations and Corporate Development

Email: ir@fractyl.com
Phone: 951.206.1200